MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10147-024-02532-0

Медицинская библиотека · International journal of clinical oncology · 2024

The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study.

Sato Sho, Ssuzuki Takashi, Chinen Takashi, Yamaguchi Hironori, Suzuki Yusuke, Hokamura Nobukazu, Saze Zenichiro, Kono Koji, Takahashi Keita, Yano Fumiaki, Kunisaki Chikara, Kosaka Takashi, Endo Itaru, Ichikawa Yasushi, Miyawaki Yutaka, Sato Hiroshi, Shimada Hideaki

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

The real-world efficacy, feasibility, and prognostic factors of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer are not fully established.

METHODS

This multi-institutional retrospective cohort study evaluated 71 consecutive patients treated with immune-checkpoint inhibitor combination therapy for esophageal cancer between March 2021 and December 2022. We assessed tumor response, safety, and long-term survival.

RESULTS

In patients with measurable lesions, the response rate was 58%, and the disease control rate for all enrolled patients was 80%. Five patients (7.0%) underwent successful conversion surgery. Grade 3 or higher immune-related adverse events occurred in 13% of patients, and one patient (1.4%) died due to cholangitis. Median progression-free survival was 9.7 (95% confidence interval: 6.5-not reached). C-reactive protein levels and performance status were identified as significant predictors of progression-free survival through Cox proportional hazards analysis.

CONCLUSIONS

Immune-checkpoint inhibitor combination therapy for esophageal cancer demonstrated comparable tumor response, safety, and long-term survival to previous randomized clinical trials. Patients with good performance status and low C-reactive protein levels may be suitable candidates for this treatment.

Для цитирования: Sato Sho, Ssuzuki Takashi, Chinen Takashi, Yamaguchi Hironori, Suzuki Yusuke, Hokamura Nobukazu, Saze Zenichiro, Kono Koji, Takahashi Keita, Yano Fumiaki, Kunisaki Chikara, Kosaka Takashi, Endo Itaru, Ichikawa Yasushi, Miyawaki Yutaka, Sato Hiroshi, Shimada Hideaki. The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study.. International journal of clinical oncology. 2024. DOI: 10.1007/s10147-024-02532-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.